HSA-coated intrinsically radiolabeled [(177)Lu]Lu₂O₃ nanoparticles for injectable nanoscale brachytherapy: Preclinical validation and first-in-human imaging.
Injectable nanoparticles designed for targeted radiation showed promising tumor targeting in animals and early feasibility in initial human imaging.
This preclinical validation with first-in-human imaging feasibility examined HSA-coated intrinsically radiolabeled [(177)Lu]Lu₂O₃ nanoparticles for injectable nanoscale brachytherapy: Preclinical validation and first-in-human imaging. The nanoparticle platform showed preclinical tumor retention and dosimetry feasibility plus first-in-human imaging, supporting further study of injectable nanoscale brachytherapy.
What the study was
- Study design
- Preclinical validation with first-in-human imaging feasibility
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Nanomedicine : nanotechnology, biology, and medicine
Why it surfaced
Retained after review of PubMed metadata and abstract because its preclinical validation with first-in-human imaging feasibility directly informs novel therapeutics; scoring was capped conservatively for design and evidence maturity.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.